Depression among patients with methadone and buprenorphine maintenance treatment in the northern mountainous areas of vietnam: prevalence and related factors
Main Article Content
Abstract
Studies have shown that depression is the most common psychiatric comorbidity in drug-dependent patients in opioid substitution treatment. The objective of this study was to investigate the prevalence of depression and related factors for depression in drug-dependent patients in methadone and buprenorphine maintenance treatment. We performed a descriptive cross-sectional study in 3 methadone maintenance therapy (MMT) service units from the northern mountainous provinces of Vietnam on 344 patients enrolling in treatment from March to December 2019. The PHQ-2 depression screening scale were used to assess depression among patients. Results: The prevalence of depression (PHQ- 2 ≥ 2) overall was 7,3%, of which methadone patients represent 1,7% and buprenorphine patients 10,2%, (p <0,05). Risk factors for depression were buprenorphine maintenance treatment (p = 0,019). Research has shown a relative prevalence of depression in opioid addiction treatment patients, suggesting the need for appropriate supportive services to improve the effectiveness of the opioid substitution program in Vietnam.
Article Details
Keywords
Methadone, Buprenorphine, depression, treatment of opioid addiction
References
2. Nguyen TTM, Nguyen LT, Pham MD, Vu HH, Mulvey KP. Methadone Maintenance Therapy in Vietnam: An Overview and Scaling-Up Plan. Advances in Preventive Medicine. Published November 25, 2012. Accessed September 21, 2020. https://www.hindawi.com/journals/apm/2012/732484/.
3. Ghabrash MF, Bahremand A, Veilleux M, et al. Depression and Outcomes of Methadone and Buprenorphine Treatment Among People with Opioid Use Disorders: A Literature Review. J Dual Diagn. 2020;16(2):191-207. doi:10.1080/15504263.2020.1726549.
4. Astals M, Díaz L, Domingo-Salvany A, Martín-Santos R, Bulbena A, Torrens M. Impact of Co-Occurring Psychiatric Disorders on Retention in a Methadone Maintenance Program: An 18-Month Follow-Up Study. Int J Environ Res Public Health. 2009;6(11):2822. doi:10.3390/ijerph6112822.
5. Peles E, Schreiber S, Naumovsky Y, Adelson M. Depression in methadone maintenance treatment patients: Rate and risk factors. J Affect Disord. 2007;99(1-3):213-220. doi:10.1016/j.jad.2006.09.017.
6. Poirier M-F, Laqueille X, Jalfre V, et al. Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):267-272. doi:10.1016/j.pnpbp.2003.10.003.
7. Havard A, Teesson M, Darke S, Ross J. Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS). J Subst Abuse Treat. 2006;30(4):355-362. doi:10.1016/j.jsat.2006.03.012.
8. Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry. 2004;19(8):510-513. doi:10.1016/j.eurpsy.2004.09.002.
9. Yin W, Pang L, Cao X, et al. Factors associated with depression and anxiety among patients attending community-based methadone maintenance treatment in China: Depression and anxiety among MMT clients. Addiction. 2015;110:51-60. doi:10.1111/add.12780.
10. Baharudin A, Mislan N, Ibrahim N, Sidi H, Nik Jaafar NR. Depression in male patients on methadone maintenance therapy: Depression in men on MMT. Asia-Pac Psychiatry. 2013;5:67-73. doi:10.1111/appy.12069
11. Nguyễn Thu Trang, Nguyễn Bích Diệp, Văn Đình Hòa, Bùi Nguyên Hồng, Lê Minh Giang. Nguy cơ rối loạn tâm thần ở bệnh nhân điều trị methadone và một số yếu tố liên quan. Tạp Chí Nghiên Cứu Học. 2016;(99):147-154.
12. Le TA, Le MQT, Dang AD, et al. Multi-level predictors of psychological problems among methadone maintenance treatment patients in difference types of settings in Vietnam. Subst Abuse Treat Prev Policy. 2019;14(1):39. doi:10.1186/s13011-019-0223-4.
13. Serafini G, Adavastro G, Canepa G, et al. The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review. Int J Mol Sci. 2018;19(8). doi:10.3390/ijms19082410.
14. Arroll B, Goodyear-Smith F, Crengle S, et al. Validation of PHQ-2 and PHQ-9 to Screen for Major Depression in the Primary Care Population. Ann Fam Med. 2010;8(4):348-353. doi:10.1370/afm.1139.
15. Sức khỏe tâm thần ở Việt Nam. Accessed September 22, 2020. https://www.who.int/vietnam/vi/health-topics/mental-health.
16. Nguyen LH, Tran BX, Nguyen HLT, et al. Psychological Distress Among Methadone Maintenance Patients in Vietnamese Mountainous Areas. AIDS Behav. 2017;21(11):3228-3237. doi:10.1007/s10461-017-1779-5.
17. Wang JL. Rural–urban differences in theprevalence of major depression and associatedimpairment. Soc Psychiatry Psychiatr Epidemiol. 2004;39(1):19-25. doi:10.1007/s00127-004-0698-8.
18. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60(1):39-50. doi:10.1016/S0376-8716(00)80006-X.
19. Šimunović M, Martinac M, Dragić M, Bevanda M, Babić D. Anxiety and depression in opiate addicts treated with methadone and buprenorphine. Alcohol Psychiatry Res J Psychiatr Res Addict. 2014;50(2):123–137.
20. Falcon E, Browne CA, Leon RM, et al. Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors. Neuropsychopharmacology. 2016;41(9):2344-2351. doi:10.1038/npp.2016.38.
21. Brooner RK, Kidorf M. Using Behavioral Reinforcement To Improve Methadone Treatment Participation. Sci Pract Perspect. 2002;1(1):38-47.
22. Instrument: Patient Health Questionnaire-2 (PHQ-2) | NIDA CTN Common Data Elements. Accessed September 25, 2020. https://cde.drugabuse.gov/instrument/fc216f70-be8e-ac44-e040-bb89ad433387.